Skip to main content
Log in

Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

This study examined the promoter methylation of APO-1/CD95 (Fas) gene in bladder urothelial carcinoma and analyzed the relationship between the Fas promoter methylation and the biological behavior of bladder cancer. Promoter methylation of Fas gene was detected by methylation-specific PCR (MSP) in 4 bladder cancer cell lines, 50 human bladder urothelial carcinoma samples and l0 normal bladder tissue samples. Correlation of the aberrant methylation of Fas promoter with the clinicopathological parameters was statistically analyzed. The results showed that Fas was down-regulated at both mRNA and protein level in bladder cancer cell lines and tissue samples of bladder urothelial carcinoma. The positive rate of Fas protein expression in bladder urothelial carcinoma was 34.0% (17/50), significantly lower than that in normal bladder tissues (70.0%, 7/10) (P<0.01). Fas promoter methylation was detected, and the positive rate of Fas promoter methylation in bladder urothelial carcinoma was 42.0% (21/50), which was obviously higher than that in normal bladder tissues (0.0%, 0/10) (P<0.01). The aberrant methylation of Fas promoter was reversely correlated with Fas protein expression (P<0.05). Furthermore, the positive rates of Fas promoter methylation in high-grade and low-grade bladder urothelial carcinoma were 73.3% (11/15) and 34.2% (12/35), respectively, with significant difference shown (P<0.05). No statistical significance was found in the Fas promoter methylation among different clinical stages of bladder cancer. It was concluded that Fas promoter hypermethylation plays an important role in the pathogenesis of bladder urothelial carcinoma and may serve as a prognostic indicator of bladder urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hu ZB. The expression and significance of Fas in human body. Sect Immunol Foreig Med Sci (Chinese), 2000,23(1):8–11

    Google Scholar 

  2. Chinnaiyan AM, O’Rourke K, Tewari M, et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 1995,81(4):505–512

    Article  PubMed  CAS  Google Scholar 

  3. Boldin MP, Mett IL, Varfolomeev EE, et al. Self-association of the “death domains” of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem, 1995,270(1):387–391

    Article  PubMed  CAS  Google Scholar 

  4. Luo B. The expression of VEGF and E-cadherin in bladder transitional carcinoma tissue. Acta Academiae Medicinae Qingdao Universitatis (Chinese), 2005,41(4):317–319

    CAS  Google Scholar 

  5. Chinnaiyan, AM, O’Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science, 1996,274(5289): 990–992

    Article  PubMed  CAS  Google Scholar 

  6. Trauzold A, Schmiedel S, Röder C, et al. Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer, 2003,89(9): 1714–1721

    Article  PubMed  CAS  Google Scholar 

  7. Tourneur L, Mistou S, Michiels FM, et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene, 2003,22(18): 2795–2804

    Article  PubMed  CAS  Google Scholar 

  8. Mishima K, Nariai Y, Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int J Cancer, 2003, 105(5):593–600

    Article  PubMed  CAS  Google Scholar 

  9. Jeltsch A. Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem, 2002,3(4):274–293

    Article  PubMed  CAS  Google Scholar 

  10. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol, 2005,17(1):55–60

    Article  PubMed  CAS  Google Scholar 

  11. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res, 2001,61(8):3225–3229

    PubMed  CAS  Google Scholar 

  12. Natarajan AT, Vermeulen S, Darroudi F, et al. Chromosomal localization of human O6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis, 1992,7(1):83–85

    Article  PubMed  CAS  Google Scholar 

  13. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res, 2001,61(12):4689–4692

    PubMed  CAS  Google Scholar 

  14. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res, 2000,60(9):2368–2371

    PubMed  CAS  Google Scholar 

  15. Srivenugopal KS, Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a prote olytic target for the E6 human papillomavirus oncoprotein. Oncogene, 2002,21(38):5940–5945

    Article  PubMed  CAS  Google Scholar 

  16. Zheng CQ, Ji SP, Gong F, et al. Detection of hypermethylated MGMT, hMLH1 and hMSH2 genes in tumor and serum DNA of gliomas patients. J Med Mol Biol (Chinese), 2009,6(1):1–5

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhangqun Ye  (叶章群).

Additional information

This project was supported by a grant from the Science and Technology Program of Yunnan Province of China (No. 2010ZC209).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, W., Xia, D., Wang, Y. et al. Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 31, 794–798 (2011). https://doi.org/10.1007/s11596-011-0679-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-011-0679-6

Key words

Navigation